The Medicare GLP-1 Bridge program launches in two days, and millions of Medicare beneficiaries are asking the same question: Do I qualify?
Starting July 1, 2026, eligible Medicare Part D enrollees can access Wegovy (semaglutide), Zepbound (tirzepatide, KwikPen formulation only), and Foundayo (orforglipron, an oral GLP-1 option) for a $50 monthly copay. The program is designed to provide a temporary bridge to broader Medicare GLP-1 coverage while the Centers for Medicare and Medicaid Services works to establish a permanent framework.
This guide covers everything patients and their physicians need to know before July 1.
Who Qualifies: The BMI and Clinical Criteria
To be eligible for the GLP-1 Bridge, a Medicare Part D enrollee must meet one of the following clinical criteria. A physician must document the relevant criterion at the time of prescribing.
According to CMS, qualification requires a BMI of:
- BMI ≥ 35 with no additional clinical condition required , or
- BMI ≥ 30 with at least one of : heart failure, uncontrolled hypertension, or chronic kidney disease, or
- BMI ≥ 27 with at least one of : pre-diabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease.
These are the same general criteria used in the approved indication for Wegovy and in the FDA labeling for GLP-1 drugs for cardiovascular risk reduction. The lowest BMI threshold (27) is for patients with a history of specific high-risk cardiovascular events or pre-diabetes.
Who Is Excluded: Critical Clarifications
This is where patients and prescribers must be particularly careful.
According to CMS guidance and Medicare Rights Center analysis, the following individuals are excluded from the GLP-1 Bridge:
- Beneficiaries who are already receiving a GLP-1 drug through their existing Part D plan for type 2 diabetes, sleep apnea, or cardiovascular risk reduction. These patients should remain on their existing Part D plan, which covers the drugs at standard Part D cost-sharing terms.
- Enrollees in Medicare Advantage plans that do not have drug coverage.
- Beneficiaries in private fee-for-service plans, PACE organizations, and certain group employer waiver plans that are not eligible for the Bridge structure.
The exclusion of patients already receiving GLP-1 drugs through Part D is important: the Bridge is designed for patients who do not currently have Medicare drug coverage for their GLP-1. Patients who already have coverage should not switch to the Bridge, as doing so could disrupt their existing coverage structure.
Which Drugs Are Covered
The three GLP-1 medications covered under the Bridge are:
- Wegovy (semaglutide) — all approved formulations
- Zepbound (tirzepatide) — KwikPen formulation only (the single-dose vial and single-dose pen formulations of Zepbound are excluded)
- Foundayo (orforglipron) — the oral GLP-1 option, all formulations
All three are available at the $50 monthly copay for eligible enrollees. Manufacturer savings programs, GoodRx, and other discount tools cannot be applied to Bridge claims.
The Prescribing Documentation Requirement Physicians Must Know
This is the element that many prescribers may not yet be aware of.
According to CMS guidance, physicians who prescribe GLP-1 drugs under the Bridge must attest to the patient's clinical eligibility at the time therapy was first initiated — even if that initial prescription was written before July 1, 2026. This means that patients who have already been started on Wegovy or Zepbound for weight management in recent months may be eligible to transition to the Bridge without re-starting from scratch — but the prescriber must complete a retrospective attestation of the qualifying BMI and clinical condition at the time of initial prescription.
This retroactive documentation is processed through a central GLP-1 Bridge processor — not through the patient's individual Part D plan. The plan does not need to opt in or be involved in Bridge claims. Prior authorization requests go directly to the central processor.
Prescribers who have patients who may qualify for the Bridge starting July 1 should contact their medical billing team or EHR vendor to understand the prior authorization workflow for Bridge claims, as it differs from standard Part D prior authorization.
The $50 Copay: What It Does and Does Not Count Toward
The $50 monthly Bridge copay is a flat rate — but it operates outside the normal Part D benefit structure in important ways.
- The $50 does NOT count toward the Part D deductible.
- The $50 does NOT count toward the $2,100 annual out-of-pocket maximum.
- The Low-Income Subsidy (Medicare Extra Help) program does NOT apply to Bridge copays — meaning low-income seniors pay the full $50 regardless of their Extra Help status.
- Additional manufacturer coupons and discount programs CANNOT be applied to Bridge copays.
For some low-income beneficiaries, the $50 monthly copay may be unaffordable. KFF noted that this creates an access barrier precisely in the population where affordability is most constrained.
The Program Timeline: What Happens After December 31, 2027?
The Bridge ends December 31, 2027. What happens next is not fully established.
The program is designed to lay the groundwork for a longer-term Medicare GLP-1 coverage framework called the BALANCE Model — but CMS has already delayed the 2027 Medicare Part D component of that model, and the full 2028 implementation depends on plan participation decisions during Medicare Open Enrollment 2026 (October 15 to December 7, 2026).
Patients who start GLP-1 therapy through the Bridge and need to continue in 2028 will need to confirm that their plan has enrolled in the BALANCE Model during the 2026 Open Enrollment period.
What Patients Should Do Before July 1
- Confirm with your physician that you meet one of the three BMI-based eligibility criteria.
- Confirm that you are enrolled in an eligible Medicare Part D plan (standalone Part D or Medicare Advantage with drug coverage).
- If you are already receiving a GLP-1 drug through Part D, do not switch to the Bridge — stay on your current plan.
- Ask your physician to begin the prior authorization documentation process now. The Bridge prior authorization goes through the central processor, not your plan.
- If you receive Extra Help (Low-Income Subsidy), discuss whether the $50 monthly copay is manageable and whether alternative coverage options exist.
- Visit Medicare.gov/glp1bridge or call 1-800-MEDICARE for eligibility information.
What Happens Next
The Bridge launches July 1. Medicare Open Enrollment — where the 2028 BALANCE Model coverage transition will be determined — runs October 15 to December 7, 2026. MedicalDaily will track enrollment data, coverage transition updates, and any CMS guidance changes throughout the Bridge's active period.
The Bottom Line
The Medicare GLP-1 Bridge launches in two days. Eligibility requires meeting specific BMI and clinical criteria, and beneficiaries already receiving GLP-1 drugs through Part D are excluded. The $50 copay does not count toward the deductible or out-of-pocket cap, and Extra Help cannot be applied to Bridge claims. Prescribers must document clinical eligibility at the time of initial prescribing — even retroactively — through a central processor rather than through the patient's plan. Patients who meet the criteria and are not currently covered should act now.
